Aim 1: To develop and validate parsimonious models using A) baseline and B) longitudinal features predictive of individual adverse TB treatment outcomes. Aim 1A: To develop and validate a parsimonious model to predict individual adverse TB treatment outcomes using baseline clinical features. Aim 1B: To produce and validate a model applicable at any point during TB treatment to predict adverse outcomes using longitudinal clinical features.